Showing 2 of 2 recruiting trials for “Acid sphingomyelinase deficiency”
RecruitingNCT06192576 ↗
A Real-world Long-term Safety and Immunogenicity Study of Olipudase Alfa Therapy in Pediatric Patients Less Than 2 Years of Age With Acid Sphingomyelinase Deficiency (ASMD)
ScreenPlus: A Comprehensive, Flexible, Multi-disorder Newborn Screening Program
👨⚕️ Melissa Wasserstein, MD, Albert Einstein College of Medicine📍 9 sites📅 Started May 2021View details ↗
Get alerts when new trials open
Create a free account to follow conditions and receive trial notifications.
Create free account →